Topic: Mace Rothenberg
Pfizer didn't like being singled out in my article, Why Pfizer Can't Cure Cancer. Pfizer's new cancer drug honcho, Mace Rothenberg, naturally thinks that Anderson's theory is off-base. It helped 57% of 82 lung cancer patients whose tumors ...
Pfizer Inc announced today the discontinuation of a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an independent Data Safety Monitoring Board (DSMB) found no evidence of improvement in the ...
Pfizer announced today that it has named Mace L. Rothenberg, M.D. as Senior Vice President, Clinical Development and Medical Affairs for its Oncology Business Unit. Dr. Rothenberg comes to Pfizer from Vanderbilt where he was Professor of Medicine at the Vanderbilt ...
